Evidence map›Paper›PMID 41731636›Full record

ArticleTropical medicine and health2026

Therapeutic challenges in relapsing cutaneous and visceral leishmaniasis caused by Leishmania (Mundinia) martiniquensis in patients with advanced HIV disease from Southern Thailand.

Kobpat Phadungsaksawasdi, Nopporn Songumpai, Chanutta Swasdivanich, Pasinee Rongngern, Tanaporn Borriboon, Chatuthanai Savigamin, Narisa Brownell, Kanyarat Kraivichian, Nopadon Noppakun, Padet Siriyasatien and 2 more

Abstract read
In one paragraph

Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Molecular identification and characterization ofCurrent research in parasitology & vector-borne diseases · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kobpat PhadungsaksawasdiDivision of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Nopporn SongumpaiDivision of Infectious Diseases, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand.
Chanutta SwasdivanichDivision of Dermatology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand.
Pasinee RongngernDivision of Dermatology, Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand.
Tanaporn BorriboonDermatopathology Unit, Institute of Dermatology, Bangkok, Thailand.
Chatuthanai SavigaminDivision of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Narisa BrownellCenter of Excellence in Vector Biology and Vector-Borne Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Kanyarat KraivichianCenter of Excellence in Vector Biology and Vector-Borne Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Nopadon NoppakunDivision of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Padet SiriyasatienCenter of Excellence in Vector Biology and Vector-Borne Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Pravit AsawanondaDivision of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Kanok PreativatanyouCenter of Excellence in Vector Biology and Vector-Borne Disease, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. kanok.pr@chula.ac.th.

Funding

Thailand Science Research and Innovation Fund, Chulalongkorn University HEA_FF_68_342_3000_045
6 · The paper itself

Abstract

backgroundAutochthonous leishmaniasis has become increasingly recognized in Thailand, with Leishmania (Mundinia) martiniquensis identified as the predominant species, particularly among immunocompromised individuals. Infected immunosuppressed patients often present with complex clinical features, which can delay diagnosis and complicate treatment. Given the limited clinical data available and emerging reports of resistant infections, improved awareness, prompt diagnosis, and optimized management strategies are urgently needed to address this underrecognized pathogen in Thailand. CASE PRESENTATION: We report two patients with advanced HIV disease (AHD) from Songkhla Province, Southern Thailand, who developed chronic diffuse cutaneous leishmaniasis characterized by widespread non-ulcerative papulonodular lesions that progressed to visceral involvement. Histopathological examination of the skin nodules showed prominent dermal fibrosis with infiltration by macrophages heavily parasitized with kinetoplast-containing amastigotes, consistent with cutaneous leishmaniasis. Molecular analyses identified L. martiniquensis as the causative agent in both cases. The parasite strains (WHO codes: MHOM/TH/2022/CULE7.1 and MHOM/TH/2022/CULE7.2) were successfully isolated from the bone marrow and cutaneous biopsy of the second patient before treatment. Furthermore, the parasite was isolated again from a cutaneous biopsy of the same patient after relapse, designated MHOM/TH/2023/CULE8. Due to the high costs of liposomal amphotericin B and the unavailability of miltefosine in Thailand, contrary to the WHO guideline recommending these as first-line therapy, patients received intravenous amphotericin B deoxycholate (AmB-D) combined with oral itraconazole. Despite repeated treatment with AmB-D and itraconazole, both patients relapsed, and Case 1 died. This raises concerns about drug resistance.

conclusionsThese cases illustrate complex cutaneous manifestations and therapeutic challenges of relapsing diffuse cutaneous and visceral leishmaniasis caused by L. martiniquensis in patients with AHD from Southern Thailand. The persistence and relapse despite AmB-D therapy raise concerns about emerging drug-resistant strains and underscore the need for enhanced surveillance, parasite isolation, and optimized treatment strategies for this neglected pathogen. Moreover, this report expands the understanding of the cutaneous spectrum of L. martiniquensis in patients with AHD, emphasizing the importance of including leishmaniasis in the differential diagnosis of complex skin diseases among immunosuppressed individuals, particularly in endemic areas.

Indexed as

Diffuse cutaneous leishmaniasisLeishmania martiniquensisMundiniaNon-ulcerated lesionsRelapseVisceral leishmaniasis

Identifiers

PMID41731636
PMCPMC13001287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.